New Managed Care and Specialty Pharmacy Study Findings Recently Were Reported by Researchers at Genentech Inc. (Impact of copay maximizers on total patient liability among patients using specialty medicines): Drugs and Therapies – Managed Care and Specialty Pharmacy

2025 OCT 03 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Daily -- Data detailed on Drugs and Therapies - Managed Care and Specialty Pharmacy have been presented. According to news reporting from South San Francisco, California, by NewsRx journalists, research stated, “Insurers increasingly use copay maximizer programs to control costs. Although these programs shield patients from out-of-pocket (OOP) exposure for drugs, the impact on OOP costs for other health care services is unknown.”

The news correspondents obtained a quote from the research from Genentech Inc., “To examine the impact of copay maximizer programs on overall patient liability for all health care services. This retrospective analysis of pharmacy and medical claims from the IQVIA PharMetrics Plus database included patients who were required to have 3 or more prescriptions (for autoimmune, multiple sclerosis, or oral oncolytic drugs) in a calendar year between 2018 and 2022 and have been continuously enrolled in a commercial plan during that year. An algorithm was applied to identify patients with presumed exposure to a copay maximizer program within each calendar year. Patients with presumed exposure to a maximizer program in a given year and no exposure to a maximizer program in prior years were eligible for the maximizer cohort. Patients without presumed exposure to a maximizer program were eligible for the nonmaximizer cohort. Eligible patients were matched 1:1 for the study cohorts. The outcome of interest was the effect of copay maximizer programs on patient liability for other health care services (via a difference-in-difference [DiD]) approach using a generalized linear mixed-effects model). In total, 5,976 patients were included in the analysis. Assuming no change in total costs from baseline to follow-up, copay maximizer programs were associated with increased patient liability for other health care services. When patient liabilities for the maximizer drug in the baseline period were $125, there was no effect on patient liabilities for other health care services (DiD [95% CI] = 0.98 [0.71-1.37]), whereas at $4,000, there was a 51% increase in patient liabilities for other health care services (1.51 [1.17-1.95]). In scenario analyses for which total costs changed from baseline to follow-up, results were similar to the base case. In the patient subgroup with no other health care patient liability at baseline ($0), a greater proportion of those who participated in a copay maximizer program had some (>$0) patient liability for other health care services in the follow-up period, compared with patients who did not participate (94.3% vs 63.2%). Our results indicated that copay maximizer programs are associated with an increase in patient liability for other health care services, especially for patients who relied heavily on the maximizer drug to meet deductible requirements or OOP maximums.”

According to the news reporters, the research concluded: “These findings should be factored into decisions and policies on implementing and regulating these programs.”

This research has been peer-reviewed.

For more information on this research see: Impact of copay maximizers on total patient liability among patients using specialty medicines. Journal of Managed Care & Specialty Pharmacy, 2025;31(10):982-990. Journal of Managed Care & Specialty Pharmacy can be contacted at: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

Our news journalists report that additional information may be obtained by contacting Achal Patel, Genentech Inc. Inc., South San Francisco, CA. Additional authors for this research include Daniel Sheinson and William B. Wong.

Publisher contact information for the Journal of Managed Care & Specialty Pharmacy is: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)